focus -WSS

focus

author：hotspot 2025-08-28 13:04:25 - browse：8

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Wikipedia

WSS

Dobbs anniversary: the lost opportunity of abortion as health care

New air purifier tech could be key to improving indoor air quality

The SUPPORT Act is critical to fighting the opioid crisis

DeSantis can now import cheaper drugs. But will Biden get credit?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Heart disease and mental health: A look at cardiac psychology

hotspot

focus

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Trump demands the U.S. pay no more for drugs than other countries … again

DIEP, the 'gold standard' of breast reconstruction, is under threat

DeSantis can now import cheaper drugs. But will Biden get credit?

23andMe had bad news about my health. I wish a person had delivered it

Caregivers of transplant patients call for more support, training

23andMe had bad news about my health. I wish a person had delivered it

Designating disabled people as health disparity population is crucial

Psychedelics group wrestles with new pharma identity

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

knowledge

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Drug repurposing or repositioning? The language matters

Malaria cases in Florida and Texas: Here’s what you need to know

Medical leaders decry Supreme Court decision on affirmative action

Trump demands the U.S. pay no more for drugs than other countries … again

JPM 2024: Verve Therapeutics looks to mainstream genome editing

focus

Wikipedia

explore

focus